Skip to Content
Get key facts and figures about chronic dry eye

Iopidine (apraclonidine ophthalmic) Disease Interactions

There are 3 disease interactions with Iopidine (apraclonidine ophthalmic):

Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Cardiovascular

Moderate Potential Hazard, Low plausibility

Applies to: Cardiovascular Disease, Hypotension, Cerebrovascular Insufficiency

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. In the central nervous system, alpha adrenergic stimulation causes an inhibition of sympathetic vasomotor centers, resulting in decreased peripheral resistance and bradycardia. While the commercially available agents in the U.S. (apraclonidine and brimonidine) are hydrophilic and do not readily distribute across the ocular-blood barrier into the CNS, prolonged use may increase the risk of systemic effects. There have been occasional reports of bradycardia, chest heaviness or burning, palpitation, reduced blood pressure, and orthostatic hypotension when apraclonidine 1% was administered once or twice a day for 4 weeks to individuals not undergoing laser surgery. Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with severe, uncontrolled cardiovascular disease, including hypertension, coronary or cerebrovascular insufficiency, recent myocardial infarction, chronic renal failure, Raynaud's disease, thromboangiitis obliterans, and a predisposition for orthostatic hypotension.

References

  1. King MH, Richards DW "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol 110 (1990): 308-9
  2. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
  3. Sridharrao B, Badrinath SS "Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery." Br J Ophthalmol 73 (1989): 884-7
View all 6 references
Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Depression

Moderate Potential Hazard, Low plausibility

Applies to: Depression

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Depression has infrequently been associated with the ocular use of these drugs due to their inhibiting effect on the sympathetic nervous system. Depressed patients should be monitored for exacerbation of their condition during therapy with ophthalmic alpha-2 adrenergic agents.

References

  1. "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Renal/Liver

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Liver Disease

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. There are limited data concerning the pharmacokinetic disposition or the clinical use of these drugs in patients with renal and/or liver disease. Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with significantly impaired renal or hepatic function.

References

  1. "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.

Iopidine (apraclonidine ophthalmic) drug Interactions

There are 738 drug interactions with Iopidine (apraclonidine ophthalmic)

Iopidine (apraclonidine ophthalmic) alcohol/food Interactions

There is 1 alcohol/food interaction with Iopidine (apraclonidine ophthalmic)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide